Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis

Company Overview

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts. These partnerships support lead optimization, biomarker identification and the generation of preclinical efficacy and safety data in preparation for eventual clinical evaluation.

Headquartered in the United States, Scinai Immunotherapeutics conducts its research and development activities primarily in North America while pursuing strategic alliances to extend its presence into European and Asian markets. The company remains focused on translating its scientific platform into robust therapeutic options, underpinned by rigorous preclinical validation and translational research initiatives.

Key Stats

• Today's Range: $0.51 to $0.61
• 50-Day Range: $0.46 to $0.91
• 52-Week Range: $0.45 to $6.18
• Volume: 168,634 shs
• Average Volume: 2.38 million shs
• Market Capitalization: $1.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Scinai Immunotherapeutics Stock Analysis - MarketRank™

Scinai Immunotherapeutics scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Scinai Immunotherapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Scinai Immunotherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Scinai Immunotherapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scinai Immunotherapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Scinai Immunotherapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.28% of the float of Scinai Immunotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Scinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.85, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scinai Immunotherapeutics has recently decreased by 12.21%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scinai Immunotherapeutics does not currently pay a dividend.

Dividend Growth

Scinai Immunotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scinai Immunotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

60.90% of the stock of Scinai Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

58.41% of the stock of Scinai Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/01/2026
• Today: 5/08/2026
• Next Earnings (Estimated): 7/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCNI
• Previous Symbol: NASDAQ:SCNI
• CIK: 1611747
• Web: www.scinai.com
• Phone: 972-8-930-2529
• Fax: 972-8930-2531
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 1.30
• Quick Ratio: 1.30

Sales & Book Value

• Annual Sales: $1.31 million
• Price / Sales: 1.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.78 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 3,536,000
• Free Float: 1,383,000
• Market Cap: $1.94 million
• Optionable: Not Optionable
• Beta: 2.19